| Net Cash Provided by (Used in) Operating Activities |
$76,091,000 |
USD |
11% |
Q1 2025 |
Q1 2025 |
| Net Cash Provided by (Used in) Financing Activities |
$30,595,000 |
USD |
141% |
Q1 2025 |
Q1 2025 |
| Net Cash Provided by (Used in) Investing Activities |
$99,997,000 |
USD |
-41% |
Q1 2025 |
Q1 2025 |
| Common Stock, Shares Authorized |
431,000,000 |
shares |
0% |
Q4 2025 |
FY 2025 |
| Common Stock, Shares, Issued |
136,941,978 |
shares |
0.38% |
Q4 2025 |
FY 2025 |
| Common Stock, Par or Stated Value Per Share |
0.0001 |
USD/shares |
0% |
Q4 2025 |
FY 2025 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect |
$6,689,000 |
USD |
-35% |
Q1 2025 |
Q1 2025 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$14,846,000 |
USD |
58% |
Q4 2025 |
FY 2025 |
| Deferred Tax Assets, Valuation Allowance |
$0 |
USD |
|
Q4 2025 |
FY 2025 |
| Deferred Tax Assets, Gross |
$24,809,000 |
USD |
-9.1% |
Q4 2025 |
FY 2025 |
| Deferred Income Tax Expense (Benefit) |
$2,870,000 |
USD |
-40% |
Q1 2025 |
Q1 2025 |
| Deferred Tax Assets, Operating Loss Carryforwards |
$16,173,000 |
USD |
14% |
Q4 2025 |
FY 2025 |
| Unrecognized Tax Benefits |
$0 |
USD |
|
Q4 2025 |
FY 2025 |
| Additional Paid in Capital |
$659,228,000 |
USD |
0.57% |
Q4 2025 |
FY 2025 |
| Deferred Tax Assets, Net of Valuation Allowance |
$24,809,000 |
USD |
-9.1% |
Q4 2025 |
FY 2025 |
| Share-based Payment Arrangement, Expense |
$3,756,000 |
USD |
63% |
Q4 2025 |
FY 2025 |